Outlook |
Featured
-
-
Outlook |
Compound screening: Fresh hunting ground
In the search for novel therapies, drug developers have begun crowdsourcing molecules.
- Annabel McGilvray
-
News Q&A |
The view from the bottom of the patent cliff
Menelas Pangalos, AstraZeneca’s head of discovery research, talks about life after patent expiration — and what it will take the turn the company around.
- Heidi Ledford
-
News |
Trade deal to curb generic-drug use
Tighter patent rules could raise drug costs in poor countries.
- Amy Maxmen
-
News |
Generic HIV drugs will widen US treatment net
Upcoming patent expiries stand to make medicines cheaper — although less convenient.
- Amy Maxmen
-
News |
US drug agency spied on scientists
Food and Drug Administration monitored five employees, defying promises about whistle-blower protection.
- Meredith Wadman
-
News Explainer |
The great gene-patent debate
How the Myriad Genetics gene-patent case might affect personalized medicine.
- Amy Maxmen
-
-
News |
Blockbuster drug bows out
Pharmaceutical industry anxiously struggles to retool as Lipitor patent expires.
- Heidi Ledford
-
News |
Indian generics giants set sights on Japan
Country's drug industry looks to exploit growing Japanese market while fending off tougher European patents.
- Priya Shetty
-
Editorial |
Change of purpose
The United States should protect investments used to find new uses for old drugs.
-
News |
China's patents push
Asia defies patent-filing downturn as global economy slips.
- David Cyranoski
-
News |
Britain grants patent for iPS cells
The first issued outside Japan for reprogrammable stem cells credits different inventors.
- Sabin Russell
Data sharing: Access all areas